Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CTSO 
Cytosorbents Crp (CTSO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: CTSO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5
1 Year Target Price $5
| 1 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -48.02% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 57.06M USD | Price to earnings Ratio - | 1Y Target Price 5 |
Price to earnings Ratio - | 1Y Target Price 5 | ||
Volume (30-day avg) 2 | Beta 1.28 | 52 Weeks Range 0.71 - 1.61 | Updated Date 09/16/2025 |
52 Weeks Range 0.71 - 1.61 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.18 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -27.32% | Operating Margin (TTM) -37.59% |
Management Effectiveness
Return on Assets (TTM) -20.1% | Return on Equity (TTM) -69.67% |
Valuation
Trailing PE - | Forward PE 7.73 | Enterprise Value 74298880 | Price to Sales(TTM) 1.58 |
Enterprise Value 74298880 | Price to Sales(TTM) 1.58 | ||
Enterprise Value to Revenue 2.06 | Enterprise Value to EBITDA -1.92 | Shares Outstanding 62761800 | Shares Floating 54981852 |
Shares Outstanding 62761800 | Shares Floating 54981852 | ||
Percent Insiders 15.46 | Percent Institutions 26.47 |
Upturn AI SWOT
Cytosorbents Crp
Company Overview
History and Background
CytoSorbents Corporation was founded in 1997. It is a critical care immunotherapy company focused on developing and commercializing blood purification technologies to treat life-threatening conditions.
Core Business Areas
- Critical Care: Develops and commercializes CytoSorb for the treatment of cytokine storm and other critical care applications.
- Cardiac Surgery: CytoSorb is used during and after cardiac surgery to reduce inflammation and improve patient outcomes.
- Licensing and Distribution: Partners with distributors to make CytoSorb available in various international markets.
Leadership and Structure
Dr. Phillip Chan is the CEO. The company operates with a functional organizational structure, with departments like R&D, Sales, Marketing, and Operations.
Top Products and Market Share
Key Offerings
- CytoSorb: CytoSorb is a blood purification technology designed to reduce excessive levels of cytokines, toxins, and other inflammatory mediators. It addresses cytokine storm, sepsis, and other inflammatory conditions. Estimations show CytoSorb accounted for a significant portion of the company's revenue. Competitors include companies that offer blood purification therapies such as Baxter International (BAX).
Market Dynamics
Industry Overview
The blood purification market is growing, driven by increasing incidence of sepsis, cytokine storm, and other inflammatory conditions. Innovation in blood purification technologies is on the rise.
Positioning
CytoSorbents is positioned as a leader in cytokine removal therapy with its CytoSorb product. It has a competitive advantage in its focus on immunomodulation in critical care.
Total Addressable Market (TAM)
The TAM for blood purification therapies is estimated to be in the billions of dollars. CytoSorbents is positioned to capture a significant portion of this market through continued innovation and market penetration.
Upturn SWOT Analysis
Strengths
- Proprietary CytoSorb technology
- Established presence in critical care market
- Growing clinical evidence supporting CytoSorb's efficacy
Weaknesses
- Reliance on a single primary product (CytoSorb)
- Relatively small size compared to major competitors
- Dependence on regulatory approvals for market expansion
Opportunities
- Expanding indications for CytoSorb
- Entering new geographic markets
- Developing next-generation blood purification technologies
Threats
- Competition from established players in blood purification
- Changes in regulatory landscape
- Potential for adverse clinical trial results
Competitors and Market Share
Key Competitors
- BAX
- XOMA
Competitive Landscape
CytoSorbents competes with larger, more established companies in the blood purification market. Its competitive advantage lies in its specialized CytoSorb technology and focus on immunomodulation. However, it faces disadvantages in terms of scale and resources.
Growth Trajectory and Initiatives
Historical Growth: CytoSorbents has experienced revenue growth driven by increasing adoption of CytoSorb, with fluctuations reflecting regulatory approvals and market penetration.
Future Projections: Future growth is projected to be driven by expanding indications for CytoSorb and geographic expansion.
Recent Initiatives: Recent initiatives include pursuing regulatory approvals for new indications, expanding the sales force, and investing in R&D.
Summary
CytoSorbents is a promising company in the blood purification market with its innovative CytoSorb technology. It is facing challenges in achieving sustained profitability and competing with larger players. Growing clinical evidence and expanding indications are working well for the company's future. Regulatory hurdles and competition are potential concerns for future success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC filings
- Analyst reports
- Industry publications
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cytosorbents Crp
Exchange NASDAQ | Headquaters Princeton, NJ, United States | ||
IPO Launch date 2013-11-07 | CEO & Director Dr. Phillip P. Chan M.D., Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 149 | Website https://www.cytosorbents.com |
Full time employees 149 | Website https://www.cytosorbents.com | ||
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. The company's flagship product is CytoSorb, an extracorporeal blood purification cartridge for the treatment of massive inflammation, organ failure, cardiothoracic surgery to remove antithrombotic drugs and inflammatory mediators that can lead to postoperative complications, such as severe bleeding, shock, failure to wean from mechanical ventilation, sepsis, and multiple organ failure; DrugSorb-ATR, an antithrombotic removal system; VetResQ, a broad-spectrum blood purification adsorber for the treatment of septic shock, toxic shock syndrome, toxin-mediated diseases, pancreatitis, trauma, liver failure, heat stroke, and lung injury in animals; PuriFi, an advanced hemoperfusion pump for blood purification therapies; and ECOS-300CY, an ex vivo organ perfusion system to preserve or improve the health and quality of harvested solid organs to be transplanted. In addition, it develops HemoDefend-BGA, a blood purification technology platform to reduce anti-A and anti-B antibodies in plasma and whole blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.